SAD patients had a longer duration of stay than patients with SZ (p = .02). Mean total
costs were significantly higher for SAD patients (p = .023). Further, we found a significant
difference in mean personnel costs (p = .02) between patients with SZ and SAD. However,
we found no significant differences in mean pharmaceutical costs (p = .12) but a
marginal difference of mean infrastructure costs (p = .05) between SZ and SAD. We
found neither a common decrease of costs over time nor a differential decrease in SZ and
SAD.